Biotech Archives - Page 39 of 795

2 minute read

Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac

May 8, 2:58 PM

Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.

GSK

2 minute read

Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher

By Vandana Singh

May 8, 1:49 PM

Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed across dosing groups.

TEVA

2 minute read

Second Death – Pfizer Reports Young Boy’s Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial

By Vandana Singh

May 8, 1:09 PM

A young patient passed away from cardiac arrest after receiving Pfizer's experimental gene therapy for Duchenne muscular dystrophy. Pfizer investigates while trials continue, including Phase 3 study. Second death associated with the therapy.

PFE

1 minute read

Tivic Health Announces Completion Of Non-Invasive VNS Study Demonstrating Effective Biological Changes In The Autonomic, Cardiac, And Central Nervous Systems

By Benzinga Newsdesk

May 8, 9:06 AM

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today the final results of their pilot research study with The

TIVC

2 minute read

CEL-SCI Receives FDA Approval For Its Confirmatory Study Of Multikine For The Treatment Of Head & Neck Cancer

By Benzinga Newsdesk

May 8, 9:03 AM

Critical milestone achieved—the FDA accepted CEL-SCI's selection criteria defining the Multikine target population before surgerySelected patient population had 73% survival with Multikine vs. 45% without Multikine based

CVM

1 minute read

PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic

By Benzinga Newsdesk

May 8, 8:39 AM

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive

PRFX

1 minute read

Neurocrine Biosciences To Begin Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1117567 In Healthy Adults

By Benzinga Newsdesk

May 8, 8:38 AM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational

NBIX

1 minute read

Acumen Pharmaceuticals Says First Patient Dosed In ALTITUDE-AD, A Phase 2 Clinical Trial Of Sabirnetug In Early Alzheimer’s Disease

By Benzinga Newsdesk

May 8, 8:28 AM

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease

ABOS

2 minute read

ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases

By Benzinga Newsdesk

May 8, 8:27 AM

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing

PRQR

1 minute read

Fulcrum Therapeutics Announces Publication Of Results From Phase 2b Clinical Trial Of Losmapimod In Facioscapulohumeral Muscular Dystrophy In The Lancet Neurology

By Benzinga Newsdesk

May 8, 8:13 AM

― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial――

FULC